Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Spermine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 known ✓ | P03372 | 1/20 | 0.48 |
| ▸ | PAOX | Q6QHF9 | 3/20 | 0.69 |
| ▸ | CA12 | O43570 | 2/20 | 0.65 |
| ▸ | F13A1 | P00488 | 2/20 | 0.65 |
| ▸ | CA2 | P00918 | 2/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.65 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.65 |
| ▸ | CA4 | P22748 | 2/20 | 0.65 |
| ▸ | CA6 | P23280 | 2/20 | 0.65 |
| ▸ | CA5A | P35218 | 2/20 | 0.65 |
| ▸ | THPO | P40225 | 2/20 | 0.65 |
| ▸ | CA7 | P43166 | 2/20 | 0.65 |
| ▸ | CA9 | Q16790 | 2/20 | 0.65 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.65 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.65 |
| ▸ | CASP2 | P42575 | 2/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.65 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.65 |
| ▸ | RECQL | P46063 | 1/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Spermine SCHEMBL7261475 | 1.00 | PAOX (0.69) | PAOXCA12F13A1CA2CYP1A2 | |
| Spermine SCHEMBL6422290 | 1.00 | PAOX (0.69) | PAOXCA12F13A1CA2CYP1A2 | |
| Spermine SCHEMBL866361 | 0.98 | PAOX (0.67) | PAOXCA12F13A1CA2CYP1A2 | |
| Spermidine SCHEMBL5615318 | 0.98 | PAOX (0.67) | PAOXCA12F13A1CA2CYP1A2 | |
| Spermidine SCHEMBL10961981 | 0.98 | PAOX (0.67) | PAOXCA12F13A1CA2CYP1A2 | |
| Spermidine SCHEMBL7264809 | 0.98 | PAOX (0.67) | PAOXCA12F13A1CA2CYP1A2 | |
| Acetic Acid SCHEMBL8379230 | 0.93 | PAOX (0.67) | PAOXCA12F13A1CA2CYP1A2 | |
| Spermine SCHEMBL5373330 | 0.90 | PAOX (0.69) | PAOXCA12F13A1CA2CYP1A2 | |
| Acetic Acid SCHEMBL134140 | 0.89 | PAOX (0.63) | PAOXCA12F13A1CA2CYP1A2 | |
| Acetic Acid SCHEMBL8629653 | 0.89 | PAOX (0.57) | PAOXCA12F13A1CA2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070276134-A1 | COMPOSITIONS AND METHODS FOR COMPLEXES OF NUCLEIC ACIDS AND ORGANIC CATIONS | NASTECH PHARMACEUTICAL COMPANY INC. (US) | 2007-11-29 | — | — | US | claimed |
| US-20070213257-A1 | COMPOSITIONS AND METHODS FOR COMPLEXES OF NUCLEIC ACIDS AND PEPTIDES | NASTECH PHARMACEUTICAL COMPANY INC. | 2007-09-13 | — | — | US | claimed |
| WO-2025226312-A1 | FC-NULL ANTI-GIP ANTIBODIES | INCREGEN THERAPEUTICS LLC (US) | 2025-10-30 | — | — | WO | disclosed |
| US-20250073301-A1 | Delayed Release Compositions of Linaclotide | IRONWOOD PHARMACEUTICALS INC (US) | 2025-03-06 | — | — | US | disclosed |
| CN-118105461-A | Treatment of abdominal pain associated with diarrhea predominant irritable bowel syndrome | 硬木药品公司 | 2024-05-31 | — | — | CN | disclosed |
| US-20230398173-A1 | Delayed Release Compositions of Linaclotide | IRONWOOD PHARMACEUTICALS INC (US) | 2023-12-14 | — | — | US | disclosed |
| US-20230346881-A1 | Stable Formulations of Linaclotide | IRONWOOD PHARMACEUTICALS INC (US) | 2023-11-02 | — | — | US | disclosed |
| US-20230346878-A1 | Treatment of Abdominal Pain Associated with Diarrhea-Predominant Irritable Bowel Syndrome | WELLS FARGO BANK, NATIONAL ASSOCIATION | 2023-11-02 | — | — | US | disclosed |
| US-20230173016-A1 | Treatment of Abdominal Pain Associated with Diarrhea-Predominant Irritable Bowel Syndrome | IRONWOOD PHARMACEUTICALS INC (US) | 2023-06-08 | — | — | US | disclosed |
| US-20230142270-A1 | Delayed Release Compositions of Linaclotide | IRONWOOD PHARMACEUTICALS INC (US) | 2023-05-11 | — | — | US | disclosed |
| CN-115089556-A | Delayed release compositions of linaclotide | 硬木药品公司 | 2022-09-23 | — | — | CN | disclosed |
| US-20110059903-A1 | Formulations Comprising Linaclotide | IRONWOOD PHARMACEUTICALS, INC. (US) | 2011-03-10 | — | — | US | disclosed |
| WO-2011017502-A9 | FORMULATIONS COMPRISING LINACLOTIDE | IRONWOOD PHARMACEUTICALS, INC. (US) | 2011-03-03 | — | — | WO | disclosed |
| WO-2011019819-A1 | ORALLY DISINTEGRATING COMPOSITIONS OF LINACLOTIDE | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2011-02-17 | — | — | WO | disclosed |
| WO-2011017502-A2 | LINACLOTIDE-CONTAINING FORMULATIONS FOR ORAL ADMINISTRATION | IRONWOOD PHARMACEUTICALS, INC. (US) | 2011-02-10 | — | — | WO | disclosed |
| WO-2010133687-A1 | CYCLOARTANONE DERIVATIVES WITH ANTICANCER ACTIVITY | PIERRE FABRE MEDICAMENT (FR) | 2010-11-25 | — | — | WO | disclosed |
| US-20070293657-A1 | COMPLEXES AND METHODS OF FORMING COMPLEXES OF RIBONUCLEIC ACIDS AND PEPTIDES | NASTECH PHARMACEUTICAL COMPANY INC. | 2007-12-20 | — | — | US | disclosed |
| US-20070276134-A1 | COMPOSITIONS AND METHODS FOR COMPLEXES OF NUCLEIC ACIDS AND ORGANIC CATIONS | NASTECH PHARMACEUTICAL COMPANY INC. (US) | 2007-11-29 | — | — | US | disclosed |
| US-20070213257-A1 | COMPOSITIONS AND METHODS FOR COMPLEXES OF NUCLEIC ACIDS AND PEPTIDES | NASTECH PHARMACEUTICAL COMPANY INC. | 2007-09-13 | — | — | US | disclosed |
| US-4591605-A | ANTISECRETORY AGENTS | RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 1986-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070276134-A1 | COMPOSITIONS AND METHODS FOR COMPLEXES OF NUCLEIC ACIDS AND ORGANIC CATIONS | NSUN2, NSUN3, POLRMT | ESR1 2910/4885PAOX 2547/4885CA12 1427/4885 |
| US-20250073301-A1 | Delayed Release Compositions of Linaclotide | LPXN, LHCGR, BRS3 | ESR1 4172/4885PAOX 3780/4885CA12 4012/4885 |
| US-20230346881-A1 | Stable Formulations of Linaclotide | LPXN, LPAR3, PDE8B | ESR1 4456/4885PAOX 2655/4885CA12 4146/4885 |
| US-20110059903-A1 | Formulations Comprising Linaclotide | LPXN, LPAR3, LPAR5 | ESR1 3908/4885PAOX 2627/4885CA12 4200/4885 |
| US-20230398173-A1 | Delayed Release Compositions of Linaclotide | LPXN, LHCGR, BRS3 | ESR1 4172/4885PAOX 3780/4885CA12 4012/4885 |
| US-20070213257-A1 | COMPOSITIONS AND METHODS FOR COMPLEXES OF NUCLEIC ACIDS AND PEPTIDES | NSUN2, NOP2, POLRMT | ESR1 3593/4885PAOX 3455/4885CA12 915/4885 |
| US-20230142270-A1 | Delayed Release Compositions of Linaclotide | LPXN, LHCGR, BRS3 | ESR1 4172/4885PAOX 3780/4885CA12 4012/4885 |
| US-20230173016-A1 | Treatment of Abdominal Pain Associated with Diarrhea-Predominant Irritable Bowel Syndrome | OPRL1, VIP, LPAR3 | ESR1 4602/4885PAOX 3165/4885CA12 3306/4885 |
| US-20230346878-A1 | Treatment of Abdominal Pain Associated with Diarrhea-Predominant Irritable Bowel Syndrome | OPRL1, VIP, LPAR3 | ESR1 4602/4885PAOX 3165/4885CA12 3306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.